Post by FDA

FDA takes major step to streamline biosimilar medicines, which are like “generic” versions of biologic drugs. New draft guidance recommends reducing unnecessary clinical pharmacokinetic (PK) testing when scientifically justified—potentially saving developers ~$20M (up to 50% of PK study costs) and helping lower drug costs for patients. https://lnkd.in/eJKtg7WM